公开(公告)号：EP3701975A1

公开(公告)日：2020-09-02

申请号：EP18869827.8

申请日：2018-10-25

申请人： Medigear International Corporation ,  Tokyo Institute of Technology

发明人： KONDOH, Shinae ,  TANAKA, Takeo

IPC分类号： A61L31/04 ,  A61K9/107 ,  A61K9/14 ,  A61K31/715 ,  A61K31/716 ,  A61K31/717 ,  A61K31/722 ,  A61K31/77 ,  A61K47/46 ,  A61K49/00 ,  A61L31/06 ,  A61L31/14 ,  A61P35/00 ,  B82Y5/00 ,  C08K5/1539 ,  C08L1/02 ,  A61K9/06 ,  A61K47/36

摘要： The present invention is directed to provide a tumor sealant that causes no serious side effects or radiation by the agent and is used in a therapy that is an improvement of a very simple and low invasiveness therapy of starving tumor cells and makes radical cure possible. The present invention relates to a particle tumor sealant that can be injected directly into needle-accessible tumor and that cuts off and/or isolates tumor tissue from surrounding tissue including blood vessels by permeating through blood vessels in the tumor site, selectively accumulating in and/or adhering to tumor tissue, swelling with water in the body, settling for a certain time and pressing tumor and peritumoral cells and/or blood vessels, and covering the whole tumor, or a particle tumor sealant that cuts off between blood vessels in a tumor site and tumor tissue.

公开(公告)号：EP3391906A1

公开(公告)日：2018-10-24

申请号：EP16875814.2

申请日：2016-12-16

申请人： Medigear International Corporation ,  Tokyo Institute of Technology ,  Farnex Incorporated

发明人： KONDOH, Shinae ,  KUCHIMARU, Takahiro ,  TANAKA, Takeo ,  ITAKURA, Shoko ,  HIJIKURO, Ichiro

IPC分类号： A61K45/00 ,  A61K9/107 ,  A61K47/14 ,  A61K49/00 ,  A61P35/00

CPC分类号： A61K9/107 ,  A61K45/00 ,  A61K47/14 ,  A61K49/00

摘要： The purpose of the invention is to provide a tumor sealant to be used for therapy that enables curative treatment, by improving an extremely simple, minimally-invasive therapy consisting of starving tumor cells without radiation exposure or causing serious side effects by drugs. The invention provides a tumor sealant that utilizes the EPR effect specific to tumor cells, that covers the tumor cells of each tissue by particles that permeate only tumor blood vessels and accumulate and settle in the tumor, that does not release angiogenesis-inducing factors, that does not separate tumor cells having improved mobility in a hypoxic state and move them to another location, that permeates gaps of from 50 nm to 500 nm of the tumor vascular endothelial cells, and that biodegrades after adhering to the tumor cells and extracellular matrix near the gaps.